SCOPUS 정보 검색 플랫폼

Annals of Hematology

Volumn 87, Issue 11, 2008, Pages 947-948

Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis

(6) Otrock, Zaher K a Mahfouz, Rami A a Charafeddine, Khalil M a Rayes, Roni F a Zahed, Laila F a Taher, Ali T a

a AMERICAN UNIVERSITY OF BEIRUT (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DNA; ETIDRONIC ACID; GENE PRODUCT; PROTEIN APA1; PROTEIN BSM1; PROTEIN TAQ1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

AGAR GEL ELECTROPHORESIS; BLOOD SAMPLING; BONE DENSITY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; GENE AMPLIFICATION; GENE FUNCTION; GENOTYPE; HUMAN; KRUSKAL WALLIS TEST; LETTER; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; THALASSEMIA; TREATMENT DURATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; GENOTYPE; HUMANS; IMIDAZOLES; OSTEOPOROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; THALASSEMIA;

EID: 53549099098 PISSN: 09395555 EISSN: None Source Type: Journal
DOI: 10.1007/s00277-008-0497-5 Document Type: Letter

Times cited : (12)

References (5)

1
- 33747828523
- Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: Results of a phase II clinical trial
- Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: Results of a phase II clinical trial. Ann Hematol 85:605-609
- (2006) Ann Hematol , vol.85 , pp. 605-609
- Otrock, Z.K.¹ Azar, S.T.² Shamseddeen, W.A.³ Habr, D.⁴ Inati, A.⁵ Koussa, S.⁶ Mahfouz, R.A.⁷ Taher, A.T.⁸

2
- 33748757909
- Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: Results from a single-center, randomized, placebo controlled trial
- Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: Results from a single-center, randomized, placebo controlled trial. Haematologica 91:1193-1202
- (2006) Haematologica , vol.91 , pp. 1193-1202
- Voskaridou, E.¹ Anagnostopoulos, A.² Konstantopoulos, K.³ Stoupa, E.⁴ Spyropoulou, E.⁵ Kiamouris, C.⁶ Terpos, E.⁷

3
- 0036243020
- Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia
- Ferrara M, Matarese SM, Francese M, Borrelli B, Coppola A, Coppola L, Esposito L (2002) Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 117:436-440
- (2002) Br J Haematol , vol.117 , pp. 436-440
- Ferrara, M.¹ Matarese, S.M.² Francese, M.³ Borrelli, B.⁴ Coppola, A.⁵ Coppola, L.⁶ Esposito, L.⁷

4
- 0032828750
- VDR genotype and response to etidronate therapy in late postmenopausal women
- Marc J, Prezelj J, Komel R, Kocijancic A (1999) VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int 10:303-306
- (1999) Osteoporos Int , vol.10 , pp. 303-306
- Marc, J.¹ Prezelj, J.² Komel, R.³ Kocijancic, A.⁴

5
- 23744498096
- Bsm I vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial
- Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F (2005) Bsm I vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 16:943-952
- (2005) Osteoporos Int , vol.16 , pp. 943-952
- Palomba, S.¹ Orio Jr., F.² Russo, T.³ Falbo, A.⁴ Tolino, A.⁵ Manguso, F.⁶ Nunziata, V.⁷ Mastrantonio, P.⁸ Lombardi, G.⁹ Zullo, F.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.